Poolbeg Pharma (LON:POLB – Get Free Report)‘s stock had its “house stock” rating reissued by stock analysts at Shore Capital Group in a research report issued on Monday,London Stock Exchange reports.
Poolbeg Pharma Price Performance
POLB opened at GBX 4.53 on Monday. The stock has a market cap of £31.91 million, a P/E ratio of -4.81 and a beta of 1.82. The stock’s 50 day simple moving average is GBX 4.33 and its 200 day simple moving average is GBX 4.19. Poolbeg Pharma has a 1-year low of GBX 2.40 and a 1-year high of GBX 5.20.
Poolbeg Pharma (LON:POLB – Get Free Report) last released its quarterly earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. Research analysts expect that Poolbeg Pharma will post -0.68 EPS for the current fiscal year.
Poolbeg Pharma Company Profile
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
Read More
- Five stocks we like better than Poolbeg Pharma
- 3 Small-Cap Stocks to Buy as the Russell 2000 Extends Its Rally
- Tapestry Stock Drops After Strong Quarter and Raised Outlook
- 3 Companies Quietly Essential to Data Center and AI Operations
- Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
